Summary of Study ST001495
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001013. The data can be accessed directly via it's Project DOI: 10.21228/M8RH7J This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001495 |
| Study Title | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
| Study Type | untargeted metabolomics |
| Study Summary | Effect of antibiotics on fecal microbiome and metabolome |
| Institute | University of California, Davis |
| Department | College of Biological Sciences |
| Laboratory | West Coast Metabolomics Center |
| Last Name | Paglia |
| First Name | Kelly |
| Address | 451 Health Sciences Drive, Room 1313 |
| kpaglia@ucdavis.edu | |
| Phone | 5307528129 |
| Submit Date | 2020-09-24 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | cdf |
| Analysis Type Detail | GC-MS |
| Release Date | 2020-10-13 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001013 |
| Project DOI: | doi: 10.21228/M8RH7J |
| Project Title: | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
| Project Type: | Double-blind randomized controlled trial |
| Project Summary: | The purpose of this study was to compare the fecal microbiome and metabolome of dogs administered enrofloxacin and metronidazole, followed by either a placebo or a bacterial/yeast synbiotic combination, for 21 days with reevaluation 8 weeks after treatment. Fecal samples were collected on days 5-7 (baseline), 26-28, and 82-84. The fecal microbiome was analyzed by qPCR and sequencing of 16S rRNA genes; time-of-flight mass spectrometry was used to determine metabolomic profiles. Split plot repeated measures ANOVAs were used to compare results between treatment groups. P < 0.05 was considered significant, with Benjamini & Hochberg’s False Discovery Rate used to adjust for multiple comparisons. Alpha diversity metrics differed significantly over time in both treatment groups, with incomplete recovery by days 82-84. Beta diversity and the dysbiosis index differed significantly over time and between treatment groups, with incomplete recovery at days 82-84 for dogs in the placebo group. Significant group-by-time interactions were noted for 15 genera, including Adlercreutzia, Bifidobacterium, Slackia, Turicibacter, Clostridium, [Ruminococcus], Erysipelotrichaceae_g_, [Eubacterium], and Succinivibrionaceae_g_. Group and time effects were present for six genera, including Collinsella, Ruminococcaceae_g_, and Prevotella. Metabolite profiles differed significantly by group-by-time, group, and time for 28, 20, and 192 metabolites, respectively. These included short-chain fatty acid, bile acid, tryptophan, sphingolipid, benzoic acid, and cinnaminic acid metabolites, as well as fucose and ethanolamine. Changes in many taxa and metabolites persisted through days 82-84. |
| Institute: | University of Tennessee |
| Department: | College of Veterinary Medicine |
| Laboratory: | Small Animal Clinical Sciences |
| Last Name: | Whittemore |
| First Name: | Jacqueline |
| Address: | 2407 River Drive, Knoxville TN 37996 |
| Email: | jwhittemore@utk.edu |
| Phone: | 865-974-8387 |
| Funding Source: | Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC |
Subject:
| Subject ID: | SU001569 |
| Subject Type: | Mammal |
| Subject Species: | Canis lupus familiaris |
| Taxonomy ID: | 9615 |
| Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Canis lupus familiaris (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment |
|---|---|---|
| SA125950 | Re_1_006 | Placebo |
| SA125951 | Re_2_030 | Placebo |
| SA125952 | Sar_1_011 | Placebo |
| SA125953 | Ra_3_053 | Placebo |
| SA125954 | Ra_2_029 | Placebo |
| SA125955 | Lu_3_055 | Placebo |
| SA125956 | Ra_1_005 | Placebo |
| SA125957 | Sar_2_035 | Placebo |
| SA125958 | Sy_1_003 | Placebo |
| SA125959 | Ty_2_038 | Placebo |
| SA125960 | Ty_3_062 | Placebo |
| SA125961 | Bi_1_023 | Placebo |
| SA125962 | Ty_1_014 | Placebo |
| SA125963 | Sy_3_051 | Placebo |
| SA125964 | Lu_2_031 | Placebo |
| SA125965 | Sy_2_027 | Placebo |
| SA125966 | Sar_3_059 | Placebo |
| SA125967 | Re_3_054 | Placebo |
| SA125968 | Cu_1_008 | Placebo |
| SA125969 | Cu_2_032 | Placebo |
| SA125970 | Cu_3_056 | Placebo |
| SA125971 | Ca_3_064 | Placebo |
| SA125972 | Ca_2_040 | Placebo |
| SA125973 | Bi_2_047 | Placebo |
| SA125974 | Lu_1_007 | Placebo |
| SA125975 | Ca_1_016 | Placebo |
| SA125976 | Gu_1_012 | Placebo |
| SA125977 | Bi_3_071 | Placebo |
| SA125978 | Ki_1_019 | Placebo |
| SA125979 | Ki_3_067 | Placebo |
| SA125980 | Gu_2_036 | Placebo |
| SA125981 | Ji_3_058 | Placebo |
| SA125982 | Ki_2_043 | Placebo |
| SA125983 | Ji_2_034 | Placebo |
| SA125984 | Gu_3_060 | Placebo |
| SA125985 | Ji_1_010 | Placebo |
| SA125986 | Po_1_018 | Synbiotic |
| SA125987 | Po_3_066 | Synbiotic |
| SA125988 | Po_2_042 | Synbiotic |
| SA125989 | Pa_2_033 | Synbiotic |
| SA125990 | Ro_1_004 | Synbiotic |
| SA125991 | Ma_3_050 | Synbiotic |
| SA125992 | Pa_1_009 | Synbiotic |
| SA125993 | Pa_3_057 | Synbiotic |
| SA125994 | Sak_3_069 | Synbiotic |
| SA125995 | To_2_044 | Synbiotic |
| SA125996 | To_3_068 | Synbiotic |
| SA125997 | Ma_2_026 | Synbiotic |
| SA125998 | To_1_020 | Synbiotic |
| SA125999 | Sak_2_045 | Synbiotic |
| SA126000 | Ro_3_052 | Synbiotic |
| SA126001 | Sak_1_021 | Synbiotic |
| SA126002 | Ro_2_028 | Synbiotic |
| SA126003 | Al_1_013 | Synbiotic |
| SA126004 | Fr_1_022 | Synbiotic |
| SA126005 | Fr_2_046 | Synbiotic |
| SA126006 | Fr_3_070 | Synbiotic |
| SA126007 | Bo_3_065 | Synbiotic |
| SA126008 | Bo_2_041 | Synbiotic |
| SA126009 | Al_2_037 | Synbiotic |
| SA126010 | Al_3_061 | Synbiotic |
| SA126011 | Bo_1_017 | Synbiotic |
| SA126012 | Gi_1_015 | Synbiotic |
| SA126013 | Gi_2_039 | Synbiotic |
| SA126014 | Ja_1_024 | Synbiotic |
| SA126015 | Ja_2_048 | Synbiotic |
| SA126016 | Ja_3_072 | Synbiotic |
| SA126017 | Go_3_049 | Synbiotic |
| SA126018 | Go_2_025 | Synbiotic |
| SA126019 | Gi_3_063 | Synbiotic |
| SA126020 | Go_1_001 | Synbiotic |
| SA126021 | Ma_1_002 | Synbiotic |
| Showing results 1 to 72 of 72 |
Collection:
| Collection ID: | CO001564 |
| Collection Summary: | Lyophilized feces |
| Sample Type: | feces |
Treatment:
| Treatment ID: | TR001584 |
| Treatment Summary: | 2, 36, Synbiotic, Placebo |
Sample Preparation:
| Sampleprep ID: | SP001577 |
| Sampleprep Summary: | Dog, Feces, 72, 10-30 mg, Lyophilized feces |
Chromatography:
| Chromatography ID: | CH001815 |
| Chromatography Summary: | Primary metabolism by GCTOF |
| Instrument Name: | LECO Pegasus IV GC-time of flight mass spectrometers |
| Column Name: | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
| Chromatography Type: | GC |
Analysis:
| Analysis ID: | AN002478 |
| Analysis Type: | MS |
| Chromatography ID: | CH001815 |
| Num Factors: | 2 |
| Num Metabolites: | 227 |
| Units: | normalized peak height |